{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:04:38Z","timestamp":1771027478582,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Newly reported hepatitis C virus (HCV) infections in California increased 50% among people 15\u201329\u2009years of age between 2014 and 2016. National estimates suggest this increase was due to the opioid epidemic and associated increases in injection drug use. However, most of California\u2019s 61 local health jurisdictions (LHJs) do not routinely investigate newly reported HCV infections, so these individuals\u2019 risk factors for infection are not well understood. We sought to describe the demographics, risk behaviors, and utilization of harm reduction services in California\u2019s fastest-rising age group of people with newly reported hepatitis C infections to support targeted HCV prevention and treatment strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>California Department of Public Health invited LHJs to participate in enhanced surveillance if they met criteria indicating heightened population risk for HCV infection among people ages 15\u201329. From June\u2013December 2018, eight LHJs contacted newly reported HCV cases by phone using a structured questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 472 total HCV cases who met the inclusion criteria, 114 (24%) completed an interview. Twenty-seven percent of respondents (<jats:italic>n<\/jats:italic>\u2009=\u200931) had ever been incarcerated, of whom 29% received a tattoo\/piercing and 39% injected drugs while incarcerated. Among people who injected drugs (PWID)\u201436% (<jats:italic>n<\/jats:italic>\u00a0=\u200941) of all respondents\u201468% shared injection equipment and many lacked access to harm reduction services: 37% knew of or ever used a needle exchange and 44% ever needed naloxone during an overdose but did not have it. Heroin was the most frequently reported injected drug (<jats:italic>n<\/jats:italic>\u00a0=\u200930), followed by methamphetamine (<jats:italic>n<\/jats:italic>\u00a0=\u200918). Pre-diagnosis HCV risk perception varied significantly by PWID status and race\/ethnicity: 76% of PWID vs. 8% of non-PWID (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and 44% of non-Hispanic White respondents vs. 22% of people of color (POC) respondents (<jats:italic>p<\/jats:italic>\u2009=\u20090.011), reported thinking they were at risk for HCV before diagnosis. Eighty-nine percent of all respondents reported having health insurance, although only two had taken HCV antiviral medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Among young people with HCV, we found limited pre-diagnosis HCV risk perception and access to harm reduction services, with racial\/ethnic disparities. Interventions to increase harm reduction services awareness, access, and utilization among young PWID, especially young PWID of color, may be warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-021-11492-3","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T12:03:35Z","timestamp":1626869015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Disparities in risk perception and low harm reduction services awareness, access, and utilization among young people with newly reported hepatitis C infections in California, 2018"],"prefix":"10.1186","volume":"21","author":[{"given":"Alison R.","family":"Ohringer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Serota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel L.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren J.","family":"Stockman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"3","key":"11492_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmeister","year":"2019","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020\u201331. https:\/\/doi.org\/10.1002\/hep.30297.","journal-title":"Hepatology"},{"key":"11492_CR2","doi-asserted-by":"publisher","unstructured":"Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet G, et al. Predictors of over-reporting HIV pre-exposure prophylaxis (PrEP) adherence among young men who have sex with men (YMSM) in self-reported versus biomarker data. AIDS Behav. 2018;22(4):1174-83. https:\/\/doi.org\/10.1007\/s10461-017-1958-4.","DOI":"10.1007\/s10461-017-1958-4"},{"issue":"2","key":"11492_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","volume":"108","author":"JE Zibbell","year":"2018","unstructured":"Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175\u201381. https:\/\/doi.org\/10.2105\/AJPH.2017.304132.","journal-title":"Am J Public Health"},{"issue":"1","key":"11492_CR4","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/S2214-109X(19)30462-0","volume":"8","author":"LA Hines","year":"2020","unstructured":"Hines LA, Trickey A, Leung J, Larney S, Peacock A, Degenhardt L, et al. Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. Lancet Glob Health. 2020;8(1):e76\u201391. https:\/\/doi.org\/10.1016\/S2214-109X(19)30462-0.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"11492_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097596","volume":"9","author":"A Lansky","year":"2014","unstructured":"Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9(5):e97596. https:\/\/doi.org\/10.1371\/journal.pone.0097596.","journal-title":"PLoS One"},{"issue":"6","key":"11492_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11524-020-00445-7","volume":"97","author":"MD Morris","year":"2020","unstructured":"Morris MD, Yen IH, Shiboski S, Evans JL, Page K. Housing stability and hepatitis C infection for young adults who inject drugs: examining the relationship of consistent and intermittent housing status on HCV infection risk. J Urban Health. 2020;97(6):831\u201344. https:\/\/doi.org\/10.1007\/s11524-020-00445-7.","journal-title":"J Urban Health"},{"issue":"6","key":"11492_CR7","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2105\/AJPH.2008.158337","volume":"100","author":"CT Williams","year":"2010","unstructured":"Williams CT, Metzger DS. Race and distance effects on regular syringe exchange program use and injection risks: a geobehavioral analysis. Am J Public Health. 2010;100(6):1068\u201374. https:\/\/doi.org\/10.2105\/AJPH.2008.158337.","journal-title":"Am J Public Health"},{"issue":"2","key":"11492_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2105\/AJPH.2003.033563","volume":"95","author":"CS Davis","year":"2005","unstructured":"Davis CS, Burris S, Kraut-Becher J, Lynch KG, Metzger D. Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. Am J Public Health. 2005;95(2):233\u20136. https:\/\/doi.org\/10.2105\/AJPH.2003.033563.","journal-title":"Am J Public Health"},{"issue":"8","key":"11492_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/10826084.2016.1268630","volume":"52","author":"N Flath","year":"2017","unstructured":"Flath N, Tobin K, King K, Lee A, Latkin C. Enduring consequences from the war on drugs: how policing practices impact HIV risk among people who inject drugs in Baltimore City. Subst Use Misuse. 2017;52(8):1003\u201310. https:\/\/doi.org\/10.1080\/10826084.2016.1268630.","journal-title":"Subst Use Misuse"},{"issue":"suppl_2","key":"11492_CR10","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/cid\/cit296","volume":"57","author":"NK Martin","year":"2013","unstructured":"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(suppl_2):S39\u201345.","journal-title":"Clin Infect Dis"},{"key":"11492_CR11","unstructured":"U.S. Centers for Disease Control and Prevention (CDC). Syringe Services Programs Fact Sheet. https:\/\/www.cdc.gov\/ssp\/docs\/SSP-FactSheet.pdf. Accessed 18 July 2021."},{"key":"11492_CR12","unstructured":"California Department of Public Health. Counties with Authorized Syringe Services Programs (SSPs) in California. https:\/\/www.cdph.ca.gov\/Programs\/CID\/DOA\/CDPH%20Document%20Library\/Map_of_SEPs.pdf. Accessed 18 July 2021."},{"key":"11492_CR13","unstructured":"California Department of Public Health. Syringe Exchange Programs in California: An Overview. https:\/\/www.cdph.ca.gov\/Programs\/CID\/DOA\/CDPH%20Document%20Library\/Overview%20SEPs%20in%20CA_2017.pdf. Accessed 18 July 2021."},{"key":"11492_CR14","unstructured":"California Department of Health Care Services. Department of Health Care Services Addresses the Opioid Crisis. [https:\/\/www.californiamat.org\/wp-content\/uploads\/2020\/05\/MAT_Flyers_DHCS_Opioid_Crisis.pdf]. Accessed 18 July 2021."},{"key":"11492_CR15","unstructured":"California Department of Health Care Services. Naloxone Distribution Project: Reducing opioid overdose deaths across California by providing free naloxone. https:\/\/www.californiamat.org\/wp-content\/uploads\/2020\/07\/MAT_Flyers_Naloxone.pdf. Accessed 18 July 2021."},{"issue":"33","key":"11492_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.15585\/mmwr.mm6933a2","volume":"69","author":"BH Lambdin","year":"2020","unstructured":"Lambdin BH, Bluthenthal RN, Wenger LD, Wheeler E, Garner B, Lakosky P, et al. Overdose education and naloxone distribution within syringe service programs\u2014United States, 2019. Morb Mortal Wkly Rep. 2020;69(33):1117\u201321. https:\/\/doi.org\/10.15585\/mmwr.mm6933a2.","journal-title":"Morb Mortal Wkly Rep"},{"key":"11492_CR17","unstructured":"U.S. Centers for Disease Control and Prevention (CDC). National Notifiable Diseases Surveillance System: Hepatitis C, Acute, 2016 Case Definition. https:\/\/ndc.services.cdc.gov\/case-definitions\/hepatitis-c-acute-2016\/. Accessed 18 July 2021."},{"key":"11492_CR18","unstructured":"U.S. Centers for Disease Control and Prevention (CDC). National Notifiable Diseases Surveillance System: Hepatitis C, Chronic, 2016 Case Definition. https:\/\/ndc.services.cdc.gov\/case-definitions\/hepatitis-c-chronic-2016\/. Accessed 18 July 2021."},{"key":"11492_CR19","unstructured":"Californai Department of Public Health. Chronic Hepatitis C in California 2018, Technical Notes. https:\/\/www.cdph.ca.gov\/Programs\/CID\/DCDC\/CDPH%20Document%20Library\/2018-Chronic-HCV-Surveillance-Report-Technical-Notes.pdf. Accessed 18 July 2021."},{"issue":"3","key":"11492_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Van Handel","year":"2016","unstructured":"Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr (1999). 2016;73(3):323.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"1","key":"11492_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1146\/annurev-publhealth-040218-043750","volume":"40","author":"DR Williams","year":"2019","unstructured":"Williams DR, Lawrence JA, Davis BA. Racism and health: evidence and needed research. Annu Rev Public Health. 2019;40(1):105\u201325. https:\/\/doi.org\/10.1146\/annurev-publhealth-040218-043750.","journal-title":"Annu Rev Public Health"},{"key":"11492_CR22","unstructured":"OpenEpi: Open Source Epidemiologic Statistics for Public Health. www.OpenEpi.com. Accessed 18 July 2021."},{"issue":"1","key":"11492_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","volume":"74","author":"SG Hosek","year":"2017","unstructured":"Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr (1999). 2017;74(1):21\u20139.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"11492_CR24","unstructured":"Association for the Advanced Study of Liver Diseases \/ Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. https:\/\/www.hcvguidelines.org. Accessed 18 July 2021."},{"key":"11492_CR25","doi-asserted-by":"publisher","first-page":"100367","DOI":"10.1016\/j.eclinm.2020.100367","volume":"22","author":"AR Ohringer","year":"2020","unstructured":"Ohringer AR, Ezer T, Serota DP. Prison-based harm reduction services are needed to address the dual substance use disorder and infectious disease epidemics in US prisons. EClinicalMedicine. 2020;22:100367. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100367.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"11492_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1037\/1064-1297.15.2.195","volume":"15","author":"LA Marsch","year":"2007","unstructured":"Marsch LA, Bickel WK, Badger GJ, Quesnel KJ. The anatomy of risk: a quantitative investigation into injection drug users\u2019 taxonomy of risk attitudes and perceptions. Exp Clin Psychopharmacol. 2007;15(2):195\u2013203. https:\/\/doi.org\/10.1037\/1064-1297.15.2.195.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"4","key":"11492_CR27","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1572-0241.2001.03728.x","volume":"96","author":"TH Tsang","year":"2001","unstructured":"Tsang TH, Horowitz E, Vugia DJ. Transmission of hepatitis C through tattooing in a United States prison. Am J Gastroenterol. 2001;96(4):1304\u20135. https:\/\/doi.org\/10.1111\/j.1572-0241.2001.03728.x.","journal-title":"Am J Gastroenterol"},{"key":"11492_CR28","volume-title":"West Coast Epidemiology Conference: 2016; Sacramento, CA","author":"K Lucas","year":"2016","unstructured":"Lucas K. Acute hepatitis C diagnosed during incarceration in California state prisons, 2011\u20132013, and proposals for prevention. In: West Coast Epidemiology Conference: 2016; Sacramento, CA; 2016."},{"key":"11492_CR29","volume-title":"Prevention and control of infections with hepatitis viruses in correctional settings","author":"C Weinbaum","year":"2003","unstructured":"Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Waltham: Massachusetts Medical Society; 2003."},{"key":"11492_CR30","unstructured":"California Department of Public Health. Chronic Hepatitis C in California 2018, Executive Summary. https:\/\/www.cdph.ca.gov\/Programs\/CID\/DCDC\/Pages\/ViralHepatitisData.aspx. Accessed 18 July 2021."},{"key":"11492_CR31","unstructured":"California Correctional Health Care Services. Hepatitis C Care Guide Summary. https:\/\/cchcs.ca.gov\/clinical-resources\/. Accessed 18 July 2021."},{"issue":"7","key":"11492_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1086\/591699","volume":"47","author":"S Aaron","year":"2008","unstructured":"Aaron S, McMahon JM, Milano D, Torres L, Clatts M, Tortu S, et al. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis. 2008;47(7):931\u20134. https:\/\/doi.org\/10.1086\/591699.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"11492_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/15332640.2017.1292418","volume":"16","author":"C McKnight","year":"2017","unstructured":"McKnight C, Shumway M, Masson CL, Pouget ER, Jordan AE, Des Jarlais DC, et al. Perceived discrimination among racial and ethnic minority drug users and the association with health care utilization. J Ethn Subst Abus. 2017;16(4):404\u201319. https:\/\/doi.org\/10.1080\/15332640.2017.1292418.","journal-title":"J Ethn Subst Abus"},{"key":"11492_CR34","unstructured":"California Department of Public Health. Chronic Hepatitis C Infections in California, 2015. Available upon request from the corresponding author."},{"key":"11492_CR35","unstructured":"U.S. Centers for Disease Control and Prevention (CDC). Persons Who Inject Drugs (PWID). https:\/\/www.cdc.gov\/pwid\/index.html. Accessed 18 July 2021."},{"issue":"5","key":"11492_CR36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","volume":"73","author":"JL Marcus","year":"2016","unstructured":"Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr (1999). 2016;73(5):540\u20136.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"12","key":"11492_CR37","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","volume":"174","author":"JI Tsui","year":"2014","unstructured":"Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974\u201381. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5416.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"11492_CR38","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","volume":"60","author":"KA Feder","year":"2017","unstructured":"Feder KA, Krawczyk N, Saloner B. Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. J Adolesc Health. 2017;60(6):747\u201350. https:\/\/doi.org\/10.1016\/j.jadohealth.2016.12.023.","journal-title":"J Adolesc Health"},{"key":"11492_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drugpo.2016.01.022","volume":"31","author":"BD Marshall","year":"2016","unstructured":"Marshall BD, Green TC, Yedinak JL, Hadland SE. Harm reduction for young people who use prescription opioids extra-medically: obstacles and opportunities. Int J Drug Policy. 2016;31:25\u201331. https:\/\/doi.org\/10.1016\/j.drugpo.2016.01.022.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"11492_CR40","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.ajem.2019.11.034","volume":"38","author":"JA Blackwell","year":"2020","unstructured":"Blackwell JA, Rodgers JB, Franco RA, Cofield SS, Walter LA, Galbraith JW, et al. Predictors of linkage to care for a nontargeted emergency department hepatitis C screening program. Am J Emerg Med. 2020;38(7):1396\u2013401. https:\/\/doi.org\/10.1016\/j.ajem.2019.11.034.","journal-title":"Am J Emerg Med"},{"key":"11492_CR41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fpubh.2019.00362","volume":"7","author":"JE Sherbuk","year":"2019","unstructured":"Sherbuk JE, McManus KA, Kemp Knick T, Canan CE, Flickinger T, Dillingham R. Disparities in hepatitis C linkage to care in the direct acting antiviral era: findings from a referral clinic with an embedded nurse navigator model. Front Public Health. 2019;7:362. https:\/\/doi.org\/10.3389\/fpubh.2019.00362.","journal-title":"Front Public Health"},{"key":"11492_CR42","doi-asserted-by":"publisher","unstructured":"Facente SN, Patel S, Hecht J, Wilson E, McFarland W, Page K, et al. Hepatitis C care cascades for three populations at high risk: low-income trans women, young people who inject drugs, and men who have sex with men and inject drugs. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab261.","DOI":"10.1093\/cid\/ciab261"},{"key":"11492_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugalcdep.2019.02.008","volume":"198","author":"MD Morris","year":"2019","unstructured":"Morris MD, Mirzazadeh A, Evans JL, Briceno A, Coffin P, Hahn JA, et al. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated. Drug Alcohol Depend. 2019;198:133\u20135. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.008.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"11492_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00486-4","volume":"18","author":"J Ziff","year":"2021","unstructured":"Ziff J, Vu T, Dvir D, Riazi F, Toribio W, Oster S, et al. Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in new York City. Harm Reduct J. 2021;18(1):1\u20138.","journal-title":"Harm Reduct J"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-11492-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-11492-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T12:03:54Z","timestamp":1626869034000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-11492-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["11492"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-11492-3","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"30 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was conducted as an extension of routine public health surveillance and was determined to be non-research by the CDPH Committee for the Protection of Human Subjects. All experimental protocols were approved by the CDPH Committee for the Protection of Human Subjects. All methods were carried out in accordance with relevant guidelines and regulations. Local health jurisdictions conducting client interviews followed existing local health jurisdiction policies for communicating with minors under the age of 18 as part of routine communicable disease case follow up. All participants were informed that participation was entirely voluntary and optional and that they could skip any question\/s they did not want to answer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1435"}}